ストックスクリーナーアプリを入手
0.4972
7.72%
-0.0416
前日終値:
$0.5388
開ける：
$0.54
24時間の取引高:
2.29M
Relative Volume:
2.90
時価総額：
$38.64M
収益：
$8.23M
当期純損益:
$-32.49M
株価収益率:
-0.9381
EPS:
-0.53
ネットキャッシュフロー:
$-19.91M
1週間 パフォーマンス:
+21.56%
1か月 パフォーマンス:
-40.81%
6か月 パフォーマンス:
-46.54%
1年 パフォーマンス:
-56.00%
1日の値動き範囲:
$0.48
$0.547
1週間の範囲:
$0.292
$0.60
52週間の値動き範囲:
$0.292
$1.65
Clearside Biomedical Inc Stock (CLSD) Company Profile
名前
Clearside Biomedical Inc
セクター
電話
678-270-3631
住所
900 NORTH POINT PARKWAY, ALPHARETTA, GA
CLSD を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLSD
Clearside Biomedical Inc
|
0.4972 | 41.87M | 8.23M | -32.49M | -19.91M | -0.53 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Clearside Biomedical Inc Stock (CLSD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-07-18 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2025-07-18 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2025-07-18 | ダウングレード | Stifel | Buy → Hold |
| 2024-08-21 | 開始されました | Chardan Capital Markets | Buy |
| 2024-06-25 | 開始されました | Oppenheimer | Outperform |
| 2021-12-15 | 再開されました | Wedbush | Outperform |
| 2021-07-29 | 開始されました | H.C. Wainwright | Buy |
| 2020-05-13 | 開始されました | ROTH Capital | Buy |
| 2019-08-09 | ダウングレード | Needham | Buy → Hold |
| 2018-11-05 | ダウングレード | Cowen | Outperform → Market Perform |
| 2018-11-05 | ダウングレード | JP Morgan | Overweight → Underweight |
| 2018-11-05 | ダウングレード | Stifel | Buy → Hold |
| 2018-03-06 | 繰り返されました | Needham | Buy |
| 2017-05-25 | 開始されました | JMP Securities | Mkt Outperform |
| 2017-02-24 | 開始されました | JP Morgan | Overweight |
| 2016-11-10 | 繰り返されました | Needham | Buy |
| 2016-10-24 | 繰り返されました | Stifel | Buy |
すべてを表示
Clearside Biomedical Inc (CLSD) 最新ニュース
Clearside Biomedical’s Phase 2b Study on CLS-AX: A New Hope for AMD Treatment - TipRanks
What drives Clearside Biomedical Inc. stock priceFree Real-Time Stock Data - PrintWeekIndia
What analysts say about Clearside Biomedical Inc. stockBreakthrough stock performance - PrintWeekIndia
Why Clearside Biomedical Inc. stock attracts strong analyst attentionFree Stock Market Analysis Courses - Newser
Clearside Biomedical Receives Canadian Approval for XIPERE® to Treat Uveitic Macular Edema via Suprachoroidal Delivery - MSN
Clearside Biomedical Announces Approval of XIPERE® - GlobeNewswire
Clearside Biomedical announces approval of XIPERE in Canada - TipRanks
Is Clearside Biomedical Inc. a good long term investmentExceptional portfolio growth - Autocar Professional
Clearside Biomedical stock soars after Health Canada approves XIPERE - Investing.com Australia
Clearside Biomedical stock soars after Health Canada approves XIPERE By Investing.com - Investing.com South Africa
Health Canada approves Clearside’s XIPERE for uveitic macular edema By Investing.com - Investing.com Nigeria
Health Canada approves Clearside’s XIPERE for uveitic macular edema - Investing.com Australia
Breakthrough Eye Treatment XIPERE Secures Major Health Canada Approval for Macular Edema - Stock Titan
Clearside Biomedical Inc. Stock Analysis and ForecastFree Market Volatility Navigation Tips - jammulinksnews.com
Clearside exploring options to advance suprachoroidal delivery platform - Eyes On Eyecare
Clearside Biomedical announces plan to explore strategic alternatives to advance its proprietary suprachoroidal space (SCS) delivery platform and promising ophthalmology pipeline - Eyes On Eyecare
Analysts Set Clearside Biomedical, Inc. (NASDAQ:CLSD) Target Price at $4.20 - Defense World
Uncovering the Potential of Clearside Biomedical Inc (CLSD) Stock - investchronicle.com
Clearside Biomedical (NASDAQ:CLSD) Downgraded by Stifel Nicolaus to "Hold" - MarketBeat
Chardan Capital Downgrades Clearside Biomedical (NASDAQ:CLSD) to Neutral - Defense World
What institutions are buying Clearside Biomedical Inc. stock nowFree Stock Trading Signals - beatles.ru
Published on: 2025-07-18 21:44:13 - Newser
Clearside Biomedical downgraded to Neutral from Buy at H.C. Wainwright - TipRanks
Health Care Stocks Stumble As Sector Faces Fresh Setbacks - Finimize
Deal Dispatch: Del Taco Tanks, Tylenol Maker Aches For Change, Joyebells Burns The Pie - Benzinga
Published on: 2025-07-18 22:42:56 - jammulinksnews.com
This Verint Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Benzinga
A Quick Look at Today's Ratings for Clearside Biomedical(CLSD.US), With a Forecast Between $0.84 to $3 - 富途牛牛
Clearside Biomedical downgraded to Neutral from Buy at Chardan - TipRanks
This Elevance Health Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
CLSD: Downgraded to Neutral by HC Wainwright & Co. | CLSD Stock News - GuruFocus
Why Clearside Biomedical Inc. stock is on top investor watchlistsHigh Return Stock Alerts - Newser
Chardan Capital downgrades Clearside Biomedical stock rating to Neutral By Investing.com - Investing.com Canada
Chardan Capital downgrades Clearside Biomedical stock rating to Neutral - Investing.com
Stifel downgrades Clearside Biomedical stock to Hold on cash concerns By Investing.com - Investing.com Nigeria
Stifel downgrades Clearside Biomedical stock to Hold on cash concerns - Investing.com Australia
Clearside Biomedical Inc (CLSD) 財務データ
収益
当期純利益
現金流量
EPS
Clearside Biomedical Inc (CLSD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Chong Ngai Hang Victor | Chief Medical Officer |
Nov 01 '24 |
Buy |
1.00 |
36,500 |
36,500 |
100,000 |
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):